MedTrace Logo

A Study of SBRT for OligoMetastatic ESCC

NCT03000816 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-01-26

No results posted yet for this study

Summary

The aim of this phase II trial is to assess progress-free survival, local control, overall survival, safety and tolerability of SBRT to treat patients with oligometastases in esophageal squamous cell carcinoma.

Conditions

  • Esophageal Squamous Cell Carcinoma Metastatic

Interventions

RADIATION

SBRT

Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Kuaile Zhao, MD. · Fudan Universtiy Shanghai Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03000816 on ClinicalTrials.gov